Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
829 participants
OBSERVATIONAL
2023-01-26
2024-01-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma
NCT05273099
Endometrial Cancer International Database
NCT04787159
Conservative Treatment for Atypical Endometrial Hyperplasia and Early Endometrial Cancer
NCT06170684
Methylated Biomarkers Predictive of Endometrial Cancer Risk
NCT06800677
Benign Reproductive Tissue Analysis for Endometrial Cancer Markers
NCT00481754
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim is to evaluate the incidence of endometrial cancer and endometrial atypical hyperplasia in patients with previous breast cancer, treated with different adjuvant therapies. The second aim is to identify ultrasonographic soft markers related with endometrial cancer or atipycal hyperplasia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAM
Patients with previous breast cancer with hormonal receptor expression that are treated with tamoxifen.
Hysteroscopy
Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
Ais
Patients with previous breast cancer with hormonal receptor expression that are treated with Ais.
Hysteroscopy
Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
No Therapy
Patients with previous breast cancer that are not treated with none hormonal therapies.
Hysteroscopy
Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hysteroscopy
Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Assumption of hormones in the previous 5 years
* Previous medical assisted reproduction technique
* Lynch syndrome or BRCA 1/2 mutations
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Palermo
OTHER
University of Padova
OTHER
Universita di Verona
OTHER
Federico II University
OTHER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER
University of Messina
OTHER
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
OTHER
Regina Elena Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Benito Chiofalo
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS "Regina Elena" National Cancer Institute
Rome, Lazio, Italy
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Regina Elena
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.